Intravitreal Bevacizumab(유리체강내 베바시주맙)란 무엇입니까?
Intravitreal Bevacizumab 유리체강내 베바시주맙 - When switched to intravitreal bevacizumab, she showed disease activity. [1] CONCLUSIONS We present a unique patient with NF1, rubeosis iridis, high IOP, and macular hemorrhages from multiple corkscrew retinal vessels in a well perfused retina, who underwent treatment with a single dose of intravitreal Bevacizumab and had an excellent response. [2] This study was proposed to assess efficacy and safety of intravitreal bevacizumab (IVB) for the treatment of mCNV across a 10-year follow-up. [3] 8%) babies were treated, most by intravitreal bevacizumab. [4] Purpose To report the clinical course of a woman treated with intravitreal bevacizumab during pregnancy. [5] Inflammatory CNVM which develops in active disease or during regression can be treated with intravitreal bevacizumab. [6] Medical records on 19 eyes of 19 patients whom intravitreal bevacizumab (IVB), intravitreal ranibizumab (IVR), and intravitreal aflibercept (IVA) injections were administered for CNV caused by PNV were enrolled into the study. [7] To investigate if preterm neonates developed systemic hypertension after intravitreal bevacizumab for retinopathy of prematurity. [8] Methods Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. [9] He was treated with oral steroids, antitubercular therapy, intravitreal bevacizumab and anterior retinal cryopexy, leading to resolution of vasculitis and vitreous haemorrhage. [10] Regardless of the presence or absence of neovascularization in the anterior segment, all patients received injections of intravitreal bevacizumab during vitrectomy. [11] However, after 3 months of discontinuation of intravitreal bevacizumab, macular edema relapsed. [12] Purpose: To determine intraocular pressure (IOP) changes after intravitreal bevacizumab or ranibizumab injection administered for various retinal disorders. [13] Purpose: To evaluate the patient satisfaction of intravitreal bevacizumab (IVB) injection services for ocular complications of diabetes mellitus (DM) at a referral center. [14] To summarize the intervention (n=10), 5 (50%) responded to LASER only, 3 (30%) required intravitreal injection with Bevacizumab (anti-VEGF) following LASER, 1 (10%) required TPPV (Trans Pars Plana Vitrectomy) in left eye for ROP stage IVb along with LASER and 1 (10%) baby required all the three- LASER, intravitreal Bevacizumab and left sided TPPV. [15] 5 years in children with severe retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB) or laser photocoagulation. [16] The objective of the present study is to determine the effects in the untreated fellow eye of intravitreal bevacizumab after a single dose in the contralateral affected eye in patients with similar retinal pathology. [17] Purpose: To evaluate acute changes in intraocular pressure (IOP) and their short-term effects on the peripapillary retinal nerve fiber layer (RNFL) thickness after intravitreal bevacizumab (IVB) injection. [18] Therefore, the patients received acetazolamide, octreotide, intravitreal bevacizumab and unspecified oral and periocular corticosteroids (1 patient); acetazolamide, intravitreal bevacizumab and unspecified oral corticosteroids (1 patient); acetazolamide, oral prednisone and intravitreal bevacizumab (1 patient); acetazolamide, intravitreal bevacizumab and unspecified oral nonsteroidal-anti-inflammatories (1 patient). [19] METHODS A 72-year-old male patient was previously treated with intravitreal bevacizumab and aflibercept for neovascular serous PED secondary to nAMD. [20] The rate of progression of ROP to stage 4 and 5 disease has decreased over time, and there has been an associated increased adoption of intravitreal bevacizumab as primary and salvage therapy. [21] However, ocular and systemic complication after intravitreal bevacizumab was the main concern. [22] We aimed to compare neurodevelopmental outcomes (NDO) of preterm infants treated for retinopathy of prematurity (ROP) with laser photocoagulation (LP), intravitreal bevacizumab (IVB) or both treatments, and to find out the effects of IVB on NDO. [23] Subfoveal choroidal neovascularization (CNV) was seen in three eyes of two patients (6%) that responded well to intravitreal bevacizumab (IVB). [24] He received systemic prednisolone, methotrexate, and intravitreal bevacizumab with partial response. [25] In all eyes, the most common first treatment was the following: intravitreal bevacizumab (38. [26] Purpose To illustrate the spectrum of clinical and imaging features in patients with unilateral Coats’ disease at baseline and in response to treatment with laser, intravitreal bevacizumab, and regional steroids. [27] In the combined group (Group 1), we treated 35 eyes of 29 persistent DME patients with a simultaneous combination of intravitreal dexamethasone and bevacizumab, and in the control group (Group 2), we treated 30 eyes of 30 patients with intravitreal bevacizumab. [28] Mean central foveal retinal thickness at presentation was 538 µm and reduced to 235 µm, after intravitreal bevacizumab. [29] Results Intravitreal bevacizumab was injected in 12 eyes (55%) and 10 patients were followed-up as a control group (45%). [30] Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity. [31] Other treatments were intravitreal bevacizumab in 3 eyes (20%), focal laser with intravitreal bevacizumab in 3 eyes (20%), PPV with focal laser (13. [32] > 20/200 vision at six months was associated with ≥ one PRP or intravitreal bevacizumab (IVB) treatment within one week of presentation or ≥ three PRP or IVB treatments overall (p <0. [33] 3%) had intravitreal bevacizumab (IVB), 2 (1. [34] Background To evaluate the outcome of intravitreal bevacizumab (IVB) and aflibercept (IVA) injection for patients with retinopathy of prematurity (ROP). [35]유리체내 베바시주맙으로 전환했을 때, 그녀는 질병 활성을 보였습니다. [1] 결론 우리는 유리체내 Bevacizumab의 단일 용량으로 치료를 받았고 우수한 반응을 보인 잘 관류된 망막의 여러 코르크 따개 망막 혈관에서 NF1, 홍채홍채증, 높은 IOP 및 황반 출혈이 있는 독특한 환자를 제시합니다. [2] 이 연구는 10년 추적 조사에 걸쳐 mCNV 치료를 위한 유리체강내 베바시주맙(IVB)의 효능과 안전성을 평가하기 위해 제안되었습니다. [3] 8%) 아기는 대부분 유리체강내 베바시주맙으로 치료를 받았습니다. [4] 목적 임신 중 유리체강내 bevacizumab으로 치료받은 여성의 임상 경과를 보고하고자 한다. [5] 활동성 질환 또는 퇴행 중에 발생하는 염증성 CNVM은 유리체내 베바시주맙으로 치료할 수 있습니다. [6] PNV에 의한 CNV에 대해 유리체강내 베바시주맙(IVB), 유리체강내 라니비주맙(IVR) 및 유리체강내 애플리버셉트(IVA) 주사를 투여한 19명의 환자 19안의 의무기록을 연구에 등록하였다. [7] 미숙아 망막병증에 대해 유리체강내 베바시주맙 투여 후 미숙아에서 전신성 고혈압이 발생했는지 조사합니다. [8] 방법 라니비주맙 또는 애플리버셉트로 전환된 유리체강내 베바시주맙에 반응하지 않는 DME 환자에 대한 단일 기관 후향적 비교 연구. [9] 그는 경구 스테로이드, 항결핵 요법, 유리체내 베바시주맙 및 전방 망막 동결고정술로 혈관염 및 유리체 출혈을 치료했습니다. [10] 전안부의 신생혈관의 유무에 관계없이 모든 환자는 유리체절제술 동안 유리체내 베바시주맙 주사를 받았다. [11] 그러나 유리체강내 베바시주맙 중단 3개월 후 황반부종이 재발했다. [12] 목적: 다양한 망막 질환에 대한 유리체강내 bevacizumab 또는 ranibizumab 주사 후 안압 변화를 알아보고자 하였다. [13] 목적: 진료의뢰센터에서 당뇨병의 안구 합병증에 대한 유리체강내 bevacizumab(IVB) 주사 서비스의 환자 만족도를 평가하고자 하였다. [14] 중재(n=10)를 요약하자면, 5명(50%)은 LASER에만 반응했고 3명(30%)은 LASER 후 Bevacizumab(항-VEGF)을 유리체강내 주사해야 했으며 1명(10%)은 TPPV(Trans Pars Plana Vitrectomy)를 필요로 했습니다. ) LASER 및 1명(10%) 아기와 함께 ROP 병기 IVb의 경우 왼쪽 눈에서 3가지 LASER, 유리체강내 Bevacizumab 및 왼쪽 TPPV가 모두 필요했습니다. [15] 유리체강내 베바시주맙(IVB) 또는 레이저 광응고술로 치료받은 중증 미숙아 망막병증(ROP)이 있는 소아에서 5년. [16] 현재 연구의 목적은 유사한 망막 병리를 가진 환자의 반대측 이환된 눈에 단일 투여 후 유리체내 베바시주맙의 치료되지 않은 동료 눈에서의 효과를 결정하는 것입니다. [17] 목적: 유리체강내 bevacizumab(IVB) 주입 후 안압의 급격한 변화와 유두주위 망막신경섬유층(RNFL) 두께에 미치는 단기적 영향을 알아보고자 하였다. [18] 따라서 환자는 acetazolamide, octreotide, intravitreal bevacizumab 및 상세불명의 경구 및 안구주위 코르티코스테로이드(환자 1명)를 투여받았습니다. 아세타졸아미드, 유리체강내 베바시주맙 및 상세불명의 경구 코르티코스테로이드(환자 1명); 아세타졸아미드, 경구 프레드니손 및 유리체내 베바시주맙(환자 1명); 아세타졸아미드, 유리체내 베바시주맙 및 상세불명의 경구 비스테로이드성 항염증제(환자 1명). [19] 행동 양식 72세 남성 환자는 이전에 nAMD에 이차적인 신생혈관 장액성 PED에 대해 유리체내 베바시주맙 및 애플리버셉트로 치료를 받은 적이 있습니다. [20] ROP가 4기 및 5기 질환으로 진행되는 속도는 시간이 지남에 따라 감소했으며, 1차 및 구제 요법으로 유리체강내 베바시주맙의 채택이 증가했습니다. [21] 그러나, 유리체강내 bevacizumab 후 안구 및 전신 합병증이 주요 관심사였습니다. [22] 우리는 미숙아 망막병증(ROP)을 레이저 광응고술(LP), 유리체강내 베바시주맙(IVB) 또는 두 가지 치료법으로 치료한 미숙아의 신경 발달 결과(NDO)를 비교하고 NDO에 대한 IVB의 영향을 알아보는 것을 목표로 했습니다. [23] 유리체강내 베바시주맙(IVB)에 잘 반응한 2명의 환자(6%)의 3안에서 중심와하 맥락막 신생혈관(CNV)이 관찰되었습니다. [24] 그는 전신 프레드니솔론, 메토트렉세이트 및 유리체강내 베바시주맙을 부분 반응으로 받았습니다. [25] 모든 눈에서 가장 흔한 1차 치료는 유리체강내 베바시주맙(38. [26] 목적 베이스라인에서 그리고 레이저, 유리체강내 베바시주맙 및 국소 스테로이드 치료에 반응하는 편측 코트병 환자의 임상 및 영상 특징의 스펙트럼을 설명하기 위해. [27] 병용군(그룹 1)에서는 29명의 지속성 DME 환자 35안을 유리체강내 덱사메타손과 베바시주맙 동시 병용요법으로 치료했으며, 대조군(그룹 2)은 30명 환자 30안을 유리체강내 베바시주맙으로 치료했다. [28] 평균 중심와 망막 프리젠테이션 시 두께는 538 µm이었고 유리체강내 bevacizumab 후 235 µm로 감소했습니다. [29] 결과 유리체강내 bevacizumab을 12안(55%)에 주사하였고 10명의 환자를 대조군(45%)으로 추시하였다. [30] 3기+미숙아 망막병증에 대한 유리체강내 베바시주맙의 효능. [31] 기타 치료는 유리체강내 bevacizumab 3안(20%), 초점 레이저 3안(20%), PPV(초점 레이저 13%)였습니다. [32] 6개월 시점의 > 20/200 시력은 1주 이내에 PRP 또는 유리체강내 베바시주맙(IVB) 치료 1회 이상 또는 전체 PRP 또는 IVB 치료 3회 이상과 관련이 있었습니다(p <0. [33] 3%)는 유리체내 베바시주맙(IVB), 2명(1. [34] 배경 미숙아 망막병증(ROP) 환자에 대한 유리체강내 베바시주맙(IVB) 및 애플리버셉트(IVA) 주사의 결과를 평가합니다. [35]
diabetic macular edema 당뇨병성 황반부종
The purpose of this study is to compare the efficacy and safety of 577-nm subthreshold micropulse laser (SML) and intravitreal bevacizumab injection (IVB) combined therapy with IVB monotherapy in the treatment of diabetic macular edema (DME). [1] Purpose To assess the effects of oral vitamin D supplement therapy on clinical outcomes of intravitreal bevacizumab (IVB) injections in patients with diabetic macular edema (DME). [2] PURPOSE To investigate the effect of the foveal Müller cell cone structure on the anatomical and functional response to intravitreal bevacizumab (IVB) treatment in patients with diabetic macular edema (DME). [3] The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization and slow progression of disease. [4] To evaluate the additional effect of ketorolac eye drops on therapeutic effects of intravitreal Bevacizumab in patients with diabetic macular edema (DME) In a randomized clinical trial, 50 patients with center involved DME (macular thickness ≥ 300 microns accompanied by decreased VA (24 < BCVA ≤ 70 ETDRS letters) were enrolled consecutively and randomized 1:1 to receive either bevacizumab plus topical ketorolac (25 patients) or bevacizumab plus artificial tears (25 patients). [5] Purpose: To report the 12-month results of laser (treatment G1) versus intravitreal bevacizumab combined with laser (treatment G2) in patients with diffuse diabetic macular edema (DME). [6] Purpose To assess the efficacy of adjuvant topical timolol–dorzolamide with intravitreal bevacizumab (IVB) injection on anatomic and functional results in eyes affected with diabetic macular edema (DME). [7] Monthly intravitreal Bevacizumab in patients with ischemic diabetic macular edema improved BCVA and macular sensitivity without compromise of perfusion in the macula. [8] Purpose To determine the characteristics of diabetic macular edema (DME) patients refractory to intravitreal bevacizumab (IVB) treatments and an additional dexamethasone implant. [9] Purpose: To identify factors that affect the therapeutic response of intravitreal bevacizumab in diabetic macular edema (DMO) and explore the correlation between the functional and anatomical outcomes observed. [10] Introduction: To assess intraocular pressure variation after intravitreal bevacizumab injection in patients with diabetic macular edema. [11]이 연구의 목적은 당뇨병성 황반부종(DME) 치료에서 577nm 역치하 미세펄스 레이저(SML) 및 유리체강내 베바시주맙 주사(IVB) 병용 요법과 IVB 단독 요법의 효능 및 안전성을 비교하는 것입니다. [1] 목적 당뇨병성 황반부종(DME) 환자에서 유리체강내 bevacizumab(IVB) 주사의 임상 결과에 대한 경구 비타민 D 보충 요법의 효과를 평가합니다. [2] nan [3] nan [4] nan [5] 목적: 미만성 당뇨병성 황반부종(DME) 환자에서 레이저(치료 G1) 대 유리체내 베바시주맙과 레이저 병용(치료 G2)의 12개월 결과를 보고합니다. [6] nan [7] nan [8] nan [9] nan [10] nan [11]
optical coherence tomography 광간섭 단층촬영
Background To explore the association of clinical characteristics and retinal microstructural features on optical coherence tomography in predicting 1-year visual response following intravitreal bevacizumab injections in eyes with visual impairment from center-involved diabetic macular edema (CI-DME). [1] Complete slit-lamp assessment, swept-source optical coherence tomography (SS-OCT) scans to measure SFCT and BCVA values were performed at two stages: baseline and one month after the third monthly injection of intravitreal bevacizumab. [2] PURPOSE To investigate the differences in natural course, intravitreal bevacizumab injection (IVB) responsiveness, and optical coherence tomography angiography findings according to the type of pigment epithelial detachment (PED) in patients with central serous chorioretinopathy (CSC). [3] Main outcome measures were visual acuity (Snellen), central foveal thickness, and central choroidal thickness as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) at baseline and at 6 month following initial intravitreal bevacizumab injection. [4] Purpose To describe the synergistic benefits and cost savings from the use of optical coherence tomography (OCT) and vascular endothelial growth factor (VEGF) inhibitors, particularly intravitreal bevacizumab, in the treatment of exudative age-related macular degeneration (AMD). [5]배경 중추 관련 당뇨병성 황반 부종(CI-DME)으로 인한 시각 장애가 있는 눈에서 유리체강내 베바시주맙 주사 후 1년 시각 반응을 예측할 때 광간섭 단층촬영에서 임상 특징과 망막 미세구조 특징의 연관성을 조사합니다. [1] 완전한 세극등 평가, SFCT 및 BCVA 값을 측정하기 위한 스위프 소스 광간섭 단층촬영(SS-OCT) 스캔은 기준선과 유리체강내 베바시주맙의 세 번째 월간 주사 후 1개월의 두 단계에서 수행되었습니다. [2] nan [3] nan [4] nan [5]
aggressive posterior retinopathy 공격성 후방망막병증
This study evaluated the efficacy of intravitreal bevacizumab (IVB) monotherapy for aggressive posterior retinopathy of prematurity (APROP) and Type 1 retinopathy of prematurity (ROP), along with recurrence rates and treatment outcomes for recurrences. [1] PURPOSE To report the clinical outcomes of combined sparing laser photocoagulation and intravitreal bevacizumab treatment compared to conventional laser photocoagulation for the treatment of aggressive posterior retinopathy of prematurity (APROP). [2] Purpose To evaluate the long-term clinical outcomes after initial management with retinal laser photocoagulation (RLP) versus intravitreal bevacizumab (IVB) injection in identical twins with zone Ⅰ aggressive posterior retinopathy of prematurity (AP-ROP). [3] The authors report a rare occurrence of bilateral cataract in eyes with aggressive posterior retinopathy of prematurity after bilateral administration of intravitreal bevacizumab in a neonate, with no evidence of lens touch. [4] Foveal development can occur after intravitreal bevacizumab (IVB) treatment for aggressive posterior retinopathy of prematurity (APROP). [5]이 연구에서는 APROP(공격성 미숙아 망막병증) 및 ROP(제1형 미숙아 망막병증)에 대한 유리체강내 베바시주맙(IVB) 단독 요법의 효과와 재발률 및 치료 결과를 평가했습니다. [1] 목적 미숙아 후부 망막병증(APROP) 치료를 위해 기존 레이저 광응고술과 비교하여 보존적 레이저 광응고술과 유리체내 베바시주맙 병용 요법의 임상 결과를 보고합니다. [2] 목적 영역 Ⅰ 공격적 미숙아 후망막병증(AP-ROP)이 있는 일란성 쌍생아에서 망막 레이저 광응고술(RLP)과 유리체내 베바시주맙(IVB) 주사로 초기 관리 후 장기 임상 결과를 평가하고자 합니다. [3] nan [4] nan [5]
retinal vein occlusion 망막 정맥 폐색
Conclusion: Intravitreal Bevacizumab is a safe and effective modality of treatment for reducing macular edema due to Central Retinal Vein Occlusion as per our study. [1] Wider use of intravitreal bevacizumab [Avastin; Roche] appears to be cost saving in the UK compared with aflibercept [Eylea; Bayer Pharma] and ranibizumab [Lucentis; Novartis] for the treatment of macular oedema from central retinal vein occlusion (CRVO), according to a cost-effectiveness analysis of the LEAVO study*. [2] The purpose of this study was to report the 5-year outcomes of treatment-naive eyes with cystoid macular edema secondary to central retinal vein occlusion treated with intravitreal bevacizumab in routine clinical practice. [3] To examine the effect of switching from intravitreal bevacizumab or ranibizumab to aflibercept in eyes with persistent macular oedema due to retinal vein occlusion (RVO). [4] OBJECTIVE To assess the anatomical and functional results of intravitreal bevacizumab injections in retinal vein occlusions at the Hospital of Instruction, Application and Reference of the Armed Forces of Yaoundé. [5]결론: 유리체강내 베바시주맙은 우리 연구에 따라 중심 망막 정맥 폐쇄로 인한 황반 부종을 감소시키는 안전하고 효과적인 치료법입니다. [1] 유리체강내 베바시주맙[Avastin; Roche]는 영국에서 alibercept[Eylea; Bayer Pharma] 및 라니비주맙[Lucentis; Novartis]는 LEAVO 연구*의 비용 효율성 분석에 따르면 중심 망막 정맥 폐쇄(CRVO)로 인한 황반 부종 치료에 사용됩니다. [2] nan [3] nan [4] nan [5]
proliferative diabetic retinopathy 증식성 당뇨망막병증
Objective: To compare efficacy of intravitreal bevacizumab augmented with Panretinal photocoagulation versus Panretinal photocoagulation alone in high risk proliferative diabetic retinopathy. [1] To investigate the efficacy of intravitreal bevacizumab injections (IVBs) for vitreous haemorrhage (VH) in proliferative diabetic retinopathy (PDR) with prior complete panretinal photocoagulation (PRP). [2] Purpose This study aimed to elucidate the effects of intravitreal bevacizumab (IVB) injections for the prevention of post-vitrectomy complications in proliferative diabetic retinopathy (PDR) patients with elevated vitreous vascular endothelial growth factor (VEGF) concentration. [3] Purpose: The current study aimed to evaluate changes in peripapillary retinal nerve fiber layer (RNFL) thickness in diabetic patients with bilateral proliferative diabetic retinopathy (PDR) after receiving panretinal photocoagulation (PRP) or intravitreal bevacizumab (IVB) with PRP. [4]목적: 고위험 증식성 당뇨망막병증에서 판레티날 광응고술로 증강된 유리체내 베바시주맙과 판레티날 광응고 단독 요법의 효능을 비교합니다. [1] 이전에 완전 범망막 광응고술(PRP)이 있었던 증식성 당뇨병성 망막병증(PDR)에서 유리체 출혈(VH)에 대한 유리체내 베바시주맙 주사(IVB)의 효능을 조사하기 위해. [2] nan [3] nan [4]
neovascular age related 신생혈관 연령 관련
To understand intraocular pressure (IOP) response after switching from intravitreal bevacizumab (IVB) and/or ranibizumab (IVR) to intravitreal aflibercept (IVA) for treatment-resistant neovascular age-related macular degeneration (nAMD) in patients with and without coexisting glaucoma-related diagnoses. [1] Purpose: To evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD). [2] Objectives: Primary objective: To assess the risk for thromboembolic events following intravitreal bevacizumab injection in neovascular age-related macular degeneration patients by a large population-based study. [3]녹내장이 동반되거나 동반되지 않은 환자의 치료 내성 신생혈관 연령 관련 황반변성(nAMD)에 대해 유리체강내 베바시주맙(IVB) 및/또는 라니비주맙(IVR)에서 유리체강내 애플리버셉트(IVA)로 전환한 후 안압(IOP) 반응을 이해하기 위해- 관련 진단. [1] 목적: 신생혈관성 연령관련 황반변성(AMD)이 있는 눈의 유리체내 반복 주사가 혈액-수성 장벽 투과성에 미치는 영향을 알아보고자 하였다. [2] nan [3]
pan retinal photocoagulation 팬 망막 광응고
A 42-year-old male patient with bilateral NVG secondary to PDR received complex management with early Ahmed valve implantation surgery, followed by pan-retinal photocoagulation (PRP) and intravitreal bevacizumab injection. [1] The treatment included intravitreal bevacizumab injection (IVBI), systemic steroid, cyclosporine and pan retinal photocoagulation. [2] The patient was treated with pan-retinal photocoagulation (PRP) with intravitreal Bevacizumab and was subsequently lost to follow-up. [3]PDR에 이차적 NVG가 있는 42세 남성 환자는 초기 Ahmed 판막 이식 수술에 이어 범망막 광응고술(PRP) 및 유리체내 베바시주맙 주사로 복잡한 관리를 받았습니다. [1] nan [2] nan [3]
type 1 retinopathy 제1형 망막병증
We report the case of 10-year-old girl who developed retinal neovascularization and vitreous hemorrhage 10 years after successful treatment of type 1 retinopathy of prematurity infant with intravitreal bevacizumab without laser ablation therapy. [1] Purpose: This study evaluates the vascular development of premature infants at 50 weeks postconception after treatment with intravitreal bevacizumab for type 1 retinopathy of prematurity (ROP). [2] PURPOSE To perform a stratified comparison of the short-term risk of retinal detachment after treatment of type 1 retinopathy of prematurity treated with panretinal photocoagulation laser versus intravitreal bevacizumab. [3]우리는 레이저 절제 요법 없이 유리체강내 bevacizumab으로 미숙아의 제1형 망막병증을 성공적으로 치료한 후 10년 후에 망막 혈관신생 및 유리체 출혈이 발생한 10세 소녀의 사례를 보고합니다. [1] nan [2] nan [3]
central serous chorioretinopathy 중심 장액 맥락망막병증
Purpose: We examined differences in the treatment effects of intravitreal bevacizumab injections and intravitreal aflibercept injections in patients with central serous chorioretinopathy. [1] Aim To report and compare the efficacy of macular grid laser versus intravitreal bevacizumab injection (IVBI) in patients with central serous chorioretinopathy (CSCR). [2]목적: 중심 장액 맥락망막병증 환자에서 유리체강내 bevacizumab 주사와 유리체강내 aplibercept 주사의 치료 효과의 차이를 조사하였다. [1] nan [2]
vascular endothelial growth 혈관 내피 성장
Vitreous humor levels of anti-vascular endothelial growth factor (VEGF) were compared between groups one, three, and seven days after intravitreal bevacizumab (0. [1] Background To evaluate alterations in the serum concentrations of vascular endothelial growth factor (VEGF) and netrin-1 after intravitreal bevacizumab (BCZ) injection for the treatment of diabetic macular edema (DME). [2]유리체강내 베바시주맙 투여 후 1일, 3일, 7일 후에 항혈관내피성장인자(VEGF)의 유리체액 수준을 비교하였다(0. [1] 배경 당뇨병성 황반부종(DME) 치료를 위한 유리체강내 베바시주맙(BCZ) 주사 후 혈관 내피 성장 인자(VEGF)와 netrin-1의 혈청 농도 변화를 평가합니다. [2]
Following Intravitreal Bevacizumab 유리체강내 베바시주맙 투여 후
IntroductionTo present a case of systemic inflammatory reaction, with associated pleural and pericardial effusions, following intravitreal bevacizumab for retinal macroaneurysm. [1] Background To explore the association of clinical characteristics and retinal microstructural features on optical coherence tomography in predicting 1-year visual response following intravitreal bevacizumab injections in eyes with visual impairment from center-involved diabetic macular edema (CI-DME). [2] Objective: We aimed to assess the incidence, management, and visual outcome of acute endophthalmitis in patients following intravitreal bevacizumab injection in a tertiary care setup. [3] Conclusion Although it is advisable to prevent IOP spikes, our study showed that use of prophylactic pressure-lowering medications with every mechanism of action has no effect in IOP spikes following intravitreal bevacizumab injections in non-glaucomatous eyes. [4] Objectives: Primary objective: To assess the risk for thromboembolic events following intravitreal bevacizumab injection in neovascular age-related macular degeneration patients by a large population-based study. [5] ABSTRACT Purpose To assess refractive errors in preterm infants following intravitreal bevacizumab (IVB) injection for retinopathy of prematurity (ROP) and to compare it with premature babies with spontaneous regressed ROP. [6]소개망막 대동맥류에 대한 유리체강내 베바시주맙 투여 후 흉막삼출액과 심낭삼출액이 동반된 전신 염증반응 1예를 소개한다. [1] 배경 중추 관련 당뇨병성 황반 부종(CI-DME)으로 인한 시각 장애가 있는 눈에서 유리체강내 베바시주맙 주사 후 1년 시각 반응을 예측할 때 광간섭 단층촬영에서 임상 특징과 망막 미세구조 특징의 연관성을 조사합니다. [2] nan [3] nan [4] nan [5] nan [6]
Monthly Intravitreal Bevacizumab 월간 유리체강내 베바시주맙
Two months after initial presentation, the patient developed neovascularization of the optic disc (NVD) in his left eye, and was treated with 3 monthly intravitreal bevacizumab injections with complete regression of the NVD. [1] She was treated with monthly intravitreal bevacizumab injections on both the eyes, for which she received a total of about 12–13 injections in each eye. [2] She underwent three monthly intravitreal bevacizumab injections in the left eye only and OCTA was repeated in both eyes one month following the last injection and showed decreased vascular density (VD) in the treated left eye but not in the untreated right eye compared to baseline. [3] Observations A 50-year-old man was treated with 3 monthly intravitreal bevacizumab injections, but despite treatment, visual acuity continued to worsen from 20/40 to 20/100, and bleeding was not receding. [4] Monthly intravitreal Bevacizumab in patients with ischemic diabetic macular edema improved BCVA and macular sensitivity without compromise of perfusion in the macula. [5]초기 내원 2개월 후, 환자는 왼쪽 눈에 시신경유두(NVD)의 신생혈관이 발생했으며 NVD가 완전히 퇴행하면서 3개월에 걸쳐 유리체강내 베바시주맙 주사를 맞았습니다. [1] 그녀는 양쪽 눈에 매달 유리체강내 베바시주맙 주사를 맞았고, 양쪽 눈에 총 12~13회 정도 주사를 맞았다. [2] nan [3] nan [4] nan [5]
Versu Intravitreal Bevacizumab 유리체강내 베바시주맙을 향하여
Purpose To evaluate the long-term clinical outcomes after initial management with retinal laser photocoagulation (RLP) versus intravitreal bevacizumab (IVB) injection in identical twins with zone Ⅰ aggressive posterior retinopathy of prematurity (AP-ROP). [1] Purpose: To report the 12-month results of laser (treatment G1) versus intravitreal bevacizumab combined with laser (treatment G2) in patients with diffuse diabetic macular edema (DME). [2] PURPOSE To perform a stratified comparison of the short-term risk of retinal detachment after treatment of type 1 retinopathy of prematurity treated with panretinal photocoagulation laser versus intravitreal bevacizumab. [3] Aim To report and compare the efficacy of macular grid laser versus intravitreal bevacizumab injection (IVBI) in patients with central serous chorioretinopathy (CSCR). [4]목적 영역 Ⅰ 공격적 미숙아 후망막병증(AP-ROP)이 있는 일란성 쌍생아에서 망막 레이저 광응고술(RLP)과 유리체내 베바시주맙(IVB) 주사로 초기 관리 후 장기 임상 결과를 평가하고자 합니다. [1] 목적: 미만성 당뇨병성 황반부종(DME) 환자에서 레이저(치료 G1) 대 유리체내 베바시주맙과 레이저 병용(치료 G2)의 12개월 결과를 보고합니다. [2] nan [3] nan [4]
Received Intravitreal Bevacizumab
The baby received intravitreal bevacizumab 0. [1] Two of the three eyes received intravitreal bevacizumab injection for aggressive posterior ROP before surgical intervention. [2] We report three patients who received intravitreal bevacizumab and/or aflibercept with worsening hypertension, proteinuria and renal injury. [3]아기는 유리체강내 베바시주맙 0을 받았습니다. [1] nan [2] nan [3]
Three Intravitreal Bevacizumab
She received three intravitreal bevacizumab [Avastin] injections until February 2017 and one intravitreal triamcinolone injection in June 2017 (approximately at the age of 55 years) for RM. [1] A further course of three intravitreal bevacizumab injections at monthly interval were initiated in both eyes, with plan for continued close monitoring and treatment. [2] A further course of three intravitreal bevacizumab injections at monthly interval were initiated in both eyes, with plan for continued close monitoring and treatment. [3]RM은 2017년 2월까지 유리체내 베바시주맙[Avastin] 주사를 3회, 2017년 6월(약 55세) 유리체내 트리암시놀론 주사 1회를 받았다. [1] nan [2] nan [3]
Receiving Intravitreal Bevacizumab 유리체강내 베바시주맙 투여
Patients were randomly assigned to receiving intravitreal bevacizumab injections every 4, 6, or 8 weeks for 1 year. [1] He had been under the care of an ophthalmologist, and had been receiving intravitreal bevacizumab injections 1. [2] An 82-year-old woman with macular degeneration receiving intravitreal bevacizumab, presented with 5-months history of muco-purulent blepharo-kerato-conjunctivitis, resistant to multiple topical antibiotics. [3]환자들은 1년 동안 4주, 6주 또는 8주마다 유리체강내 베바시주맙 주사를 받도록 무작위 배정되었습니다. [1] 그는 안과 의사의 보살핌을 받았으며 유리체강내 베바시주맙 주사 1을 받고 있었습니다. [2] nan [3]
Dose Intravitreal Bevacizumab
Half-dose intravitreal bevacizumab was used to treat the vascular condition. [1] Purpose: To compare visual acuity (VA) and central macular thickness (CMT) outcome of loading dose intravitreal bevacizumab treatment between neovascular AMD patients with character of predominant subretinal and intraretinal fluid. [2]반용량 유리체내 베바시주맙은 혈관 상태를 치료하는 데 사용되었습니다. [1] nan [2]
Scheduled Intravitreal Bevacizumab 예정된 유리체강내 베바시주맙
PATIENTS AND METHODS This cross-sectional study included DME patients who did not complete their scheduled intravitreal bevacizumab injections during the Lockdown period (March 20, 2020 to May 20, 2020). [1] Patients and Methods: This cross-sectional study included DME patients who did not complete their scheduled intravitreal bevacizumab injections during the Lockdown period (March 20, 2020 to May 20, 2020). [2]환자 및 방법 이 횡단면 연구에는 잠금 기간(2020년 3월 20일 ~ 2020년 5월 20일) 동안 예정된 유리체강내 베바시주맙 주사를 완료하지 않은 DME 환자가 포함되었습니다. [1] 환자 및 방법: 이 단면 연구에는 폐쇄 기간(2020년 3월 20일 ~ 2020년 5월 20일) 동안 예정된 유리체강내 베바시주맙 주사를 완료하지 않은 DME 환자가 포함되었습니다. [2]
Single Intravitreal Bevacizumab 단일 유리체강내 베바시주맙
AIM: To find out the efficacy of macular photocoagulation when given in the early or late period after single intravitreal bevacizumab injection in terms of central foveal thickness change and visual acuity gain. [1] Approximately one month after treatment with rapidly-tapered oral methylprednisolone and a single intravitreal bevacizumab (Avastin) injection, the retinopathy had resolved with subjective visual improvement. [2]목적: 1회 유리체강내 bevacizumab 주사 후 초기 또는 후기에 황반 광응고술을 시행했을 때 중심와두께 변화와 시력증가에 대한 효과를 알아보고자 하였다. [1] 빠르게 감소하는 경구 메틸프레드니솔론과 유리체강내 베바시주맙(아바스틴) 단일 주사로 치료한 후 약 1개월 후 망막병증은 주관적 시각 개선으로 해결되었습니다. [2]
intravitreal bevacizumab injection 유리체강내 베바시주맙 주사
A 42-year-old male patient with bilateral NVG secondary to PDR received complex management with early Ahmed valve implantation surgery, followed by pan-retinal photocoagulation (PRP) and intravitreal bevacizumab injection. [1] Intravitreal bevacizumab injection was given in the right eye; however, there was no improvement in the amount of intraretinal fluid nor visual acuity. [2] Purpose: To investigate the effects of intravitreal bevacizumab injection combined with laser photocoagulation in patients with retinal microaneurysms. [3] Introduction: Intravitreal Bevacizumab injection has now become a routine procedure for retina specialists throughout the world. [4] He was advised intravitreal bevacizumab injection (0. [5] Notably, a 6-year-old patient developed choroidal neovascularization and required treatment with intravitreal bevacizumab injections. [6] The purpose of this study is to compare the efficacy and safety of 577-nm subthreshold micropulse laser (SML) and intravitreal bevacizumab injection (IVB) combined therapy with IVB monotherapy in the treatment of diabetic macular edema (DME). [7] PATIENTS AND METHODS This cross-sectional study included DME patients who did not complete their scheduled intravitreal bevacizumab injections during the Lockdown period (March 20, 2020 to May 20, 2020). [8] Patients were randomly assigned to receiving intravitreal bevacizumab injections every 4, 6, or 8 weeks for 1 year. [9] Two months after initial presentation, the patient developed neovascularization of the optic disc (NVD) in his left eye, and was treated with 3 monthly intravitreal bevacizumab injections with complete regression of the NVD. [10] A provisional diagnosis of sub-ILM hemorrhage secondary to PCV was made and was treated with intravitreal Bevacizumab injection. [11] He had been under the care of an ophthalmologist, and had been receiving intravitreal bevacizumab injections 1. [12] Background To explore the association of clinical characteristics and retinal microstructural features on optical coherence tomography in predicting 1-year visual response following intravitreal bevacizumab injections in eyes with visual impairment from center-involved diabetic macular edema (CI-DME). [13] Treatment started with bevacizumab in all patients but in six patients was switched to aflibercept due to inadequate response to intravitreal bevacizumab injection. [14] Panretinal photocoagulation and intravitreal bevacizumab injection were applied to these eyes. [15] CONCLUSION Intravitreal bevacizumab injection can have a favorable effect in controlling intraocular pressure and pain control in patients with NVG because it decreases the angiogenesis and helps to augment the results of conventional procedures. [16] Objective: We aimed to assess the incidence, management, and visual outcome of acute endophthalmitis in patients following intravitreal bevacizumab injection in a tertiary care setup. [17] We present a case of a patient who was taking intravitreal bevacizumab injections for diabetic retinopathy and was hospitalized with worsening renal function, high blood pressure, and nephrotic-range proteinuria in the setting of tight glycemic control. [18] The efficacy of combined intravitreal bevacizumab injection with systemic chemotherapy, palliative radiotherapy, and hormonal therapy to treat choroidal and orbital metastases is not known. [19] Conclusion Although it is advisable to prevent IOP spikes, our study showed that use of prophylactic pressure-lowering medications with every mechanism of action has no effect in IOP spikes following intravitreal bevacizumab injections in non-glaucomatous eyes. [20] Purpose: We examined differences in the treatment effects of intravitreal bevacizumab injections and intravitreal aflibercept injections in patients with central serous chorioretinopathy. [21] Notably, a 6-year-old patient developed choroidal neovascularization and required treatment with intravitreal bevacizumab injections. [22] Patients and Methods: This cross-sectional study included DME patients who did not complete their scheduled intravitreal bevacizumab injections during the Lockdown period (March 20, 2020 to May 20, 2020). [23] AIM: To find out the efficacy of macular photocoagulation when given in the early or late period after single intravitreal bevacizumab injection in terms of central foveal thickness change and visual acuity gain. [24] She was treated with monthly intravitreal bevacizumab injections on both the eyes, for which she received a total of about 12–13 injections in each eye. [25] A 38-year-old woman who had previously been diagnosed and treated for unilateral Vogt-Koyanagi-Harada syndrome (VKH) and had undergone multiple intravitreal bevacizumab injections to manage inflammatory choroidal neovascularisation in her right eye, presented 2 years later with visual complains in left eye. [26] He had received two intravitreal bevacizumab injections in his left eye at outside facility. [27] CNVM in the left eye was treated successfully with a single dose of intravitreal bevacizumab injection with no further recurrence. [28] Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month. [29] Purpose: To evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD). [30] Background To analyze the functional and anatomical outcome after vitrectomy with subretinal rtPA (recombinant tissue plasminogen activator) combined with or without an intravitreal Bevacizumab injection. [31] We decided to treat her with intravitreal Bevacizumab injections in her right eye. [32] To investigate the efficacy of intravitreal bevacizumab injections (IVBs) for vitreous haemorrhage (VH) in proliferative diabetic retinopathy (PDR) with prior complete panretinal photocoagulation (PRP). [33] She underwent three monthly intravitreal bevacizumab injections in the left eye only and OCTA was repeated in both eyes one month following the last injection and showed decreased vascular density (VD) in the treated left eye but not in the untreated right eye compared to baseline. [34] Observations A 50-year-old man was treated with 3 monthly intravitreal bevacizumab injections, but despite treatment, visual acuity continued to worsen from 20/40 to 20/100, and bleeding was not receding. [35] Objectives: Primary objective: To assess the risk for thromboembolic events following intravitreal bevacizumab injection in neovascular age-related macular degeneration patients by a large population-based study. [36] PURPOSE To investigate the differences in natural course, intravitreal bevacizumab injection (IVB) responsiveness, and optical coherence tomography angiography findings according to the type of pigment epithelial detachment (PED) in patients with central serous chorioretinopathy (CSC). [37] In our case, severe atypical infective endophthalmitis occurred after an intravitreal bevacizumab injection in a patient with primary intraocular lymphoma. [38] Main outcome measures were visual acuity (Snellen), central foveal thickness, and central choroidal thickness as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) at baseline and at 6 month following initial intravitreal bevacizumab injection. [39] The treatment included intravitreal bevacizumab injection (IVBI), systemic steroid, cyclosporine and pan retinal photocoagulation. [40] A combined approach with laser photocoagulation and intravitreal bevacizumab injection was used to facilitate shrinkage of the tumor preoperatively and pars plana vitrectomy was used to remove the tumor and ERM. [41] Two of the three eyes received intravitreal bevacizumab injection for aggressive posterior ROP before surgical intervention. [42] Preoperative intravitreal bevacizumab injection (IVB) within two weeks prior to PPV and 23G vitrectomy systems was found to decrease the risk for intraoperative retinal break development (P=0. [43] Introduction: To assess intraocular pressure variation after intravitreal bevacizumab injection in patients with diabetic macular edema. [44] A further course of three intravitreal bevacizumab injections at monthly interval were initiated in both eyes, with plan for continued close monitoring and treatment. [45] BackgroundTo describe the effects of intravitreal bevacizumab injection (IVB) and/or transpupillary thermotherapy (TTT) in the treatment of small pigmented choroidal lesions with subfoveal fluid (SFF), and to investigate prognostic value of the therapeutic response in future tumor growth. [46] Aim To report and compare the efficacy of macular grid laser versus intravitreal bevacizumab injection (IVBI) in patients with central serous chorioretinopathy (CSCR). [47] A further course of three intravitreal bevacizumab injections at monthly interval were initiated in both eyes, with plan for continued close monitoring and treatment. [48] OBJECTIVE To assess the anatomical and functional results of intravitreal bevacizumab injections in retinal vein occlusions at the Hospital of Instruction, Application and Reference of the Armed Forces of Yaoundé. [49]PDR에 이차적 NVG가 있는 42세 남성 환자는 초기 Ahmed 판막 이식 수술에 이어 범망막 광응고술(PRP) 및 유리체내 베바시주맙 주사로 복잡한 관리를 받았습니다. [1] 유리체강내 베바시주맙 주사가 오른쪽 눈에 주어졌습니다. 그러나 망막내액의 양이나 시력에는 개선이 없었다. [2] 목적: 망막 미세동맥류 환자에서 유리체강내 bevacizumab 주사와 레이저 광응고술의 효과를 알아보고자 하였다. [3] 소개: 유리체강내 베바시주맙 주사는 이제 전 세계 망막 전문의에게 일상적인 절차가 되었습니다. [4] nan [5] 특히, 6세 환자는 맥락막 신생혈관이 발생하여 유리체내 베바시주맙 주사 치료가 필요했습니다. [6] 이 연구의 목적은 당뇨병성 황반부종(DME) 치료에서 577nm 역치하 미세펄스 레이저(SML) 및 유리체강내 베바시주맙 주사(IVB) 병용 요법과 IVB 단독 요법의 효능 및 안전성을 비교하는 것입니다. [7] 환자 및 방법 이 횡단면 연구에는 잠금 기간(2020년 3월 20일 ~ 2020년 5월 20일) 동안 예정된 유리체강내 베바시주맙 주사를 완료하지 않은 DME 환자가 포함되었습니다. [8] 환자들은 1년 동안 4주, 6주 또는 8주마다 유리체강내 베바시주맙 주사를 받도록 무작위 배정되었습니다. [9] 초기 내원 2개월 후, 환자는 왼쪽 눈에 시신경유두(NVD)의 신생혈관이 발생했으며 NVD가 완전히 퇴행하면서 3개월에 걸쳐 유리체강내 베바시주맙 주사를 맞았습니다. [10] PCV에 이차적인 ILM하 출혈의 잠정 진단이 내려졌고 유리체내 Bevacizumab 주사로 치료되었습니다. [11] 그는 안과 의사의 보살핌을 받았으며 유리체강내 베바시주맙 주사 1을 받고 있었습니다. [12] 배경 중추 관련 당뇨병성 황반 부종(CI-DME)으로 인한 시각 장애가 있는 눈에서 유리체강내 베바시주맙 주사 후 1년 시각 반응을 예측할 때 광간섭 단층촬영에서 임상 특징과 망막 미세구조 특징의 연관성을 조사합니다. [13] 모든 환자에서 베바시주맙으로 치료를 시작했지만 6명의 환자에서 유리체강내 베바시주맙 주사에 대한 부적절한 반응으로 인해 애플리버셉트로 전환되었습니다. [14] 이 눈에 범망막 광응고술과 유리체내 베바시주맙 주사를 적용했습니다. [15] 결론 유리체강내 베바시주맙 주사는 혈관신생을 감소시키고 기존 절차의 결과를 증가시키는 데 도움이 되기 때문에 NVG 환자의 안압 조절 및 통증 조절에 유리한 효과를 가질 수 있다. [16] nan [17] nan [18] nan [19] nan [20] 목적: 중심 장액 맥락망막병증 환자에서 유리체강내 bevacizumab 주사와 유리체강내 aplibercept 주사의 치료 효과의 차이를 조사하였다. [21] 특히, 6세 환자는 맥락막 신생혈관이 발생하여 유리체내 베바시주맙 주사 치료가 필요했습니다. [22] 환자 및 방법: 이 단면 연구에는 폐쇄 기간(2020년 3월 20일 ~ 2020년 5월 20일) 동안 예정된 유리체강내 베바시주맙 주사를 완료하지 않은 DME 환자가 포함되었습니다. [23] 목적: 1회 유리체강내 bevacizumab 주사 후 초기 또는 후기에 황반 광응고술을 시행했을 때 중심와두께 변화와 시력증가에 대한 효과를 알아보고자 하였다. [24] 그녀는 양쪽 눈에 매달 유리체강내 베바시주맙 주사를 맞았고, 양쪽 눈에 총 12~13회 정도 주사를 맞았다. [25] nan [26] nan [27] 왼쪽 눈의 CNVM은 더 이상의 재발 없이 유리체강내 베바시주맙 주사의 단일 용량으로 성공적으로 치료되었습니다. [28] ET-1의 방수 수준은 유리체내 베바시주맙 주사(IVB) 전과 1개월 후에 얻어졌습니다. [29] 목적: 신생혈관성 연령관련 황반변성(AMD)이 있는 눈의 유리체내 반복 주사가 혈액-수성 장벽 투과성에 미치는 영향을 알아보고자 하였다. [30] 배경 유리체내 베바시주맙 주사와 함께 또는 없이 조합된 망막하 rtPA(재조합 조직 플라스미노겐 활성화제)를 사용한 유리체 절제술 후 기능 및 해부학적 결과를 분석하기 위해. [31] nan [32] 이전에 완전 범망막 광응고술(PRP)이 있었던 증식성 당뇨병성 망막병증(PDR)에서 유리체 출혈(VH)에 대한 유리체내 베바시주맙 주사(IVB)의 효능을 조사하기 위해. [33] nan [34] nan [35] nan [36] nan [37] nan [38] nan [39] nan [40] nan [41] nan [42] nan [43] nan [44] nan [45] nan [46] nan [47] nan [48] nan [49]
intravitreal bevacizumab therapy
Developmental outcomes were similar between preterm infants with and without ROP or severe ROP or between ROP infants with and without intravitreal bevacizumab therapy. [1] 7 mg intravitreal implant in recalcitrant radiation maculopathy which was refractory to intravitreal bevacizumab therapy. [2] There have been several reports of cluster sterile endophthalmitis arising from intravitreal bevacizumab therapy [7–9]. [3]발달 결과는 ROP 또는 중증 ROP가 있거나 없는 조산아 또는 유리체내 베바시주맙 요법이 있거나 없는 ROP 영아 간에 유사했습니다. [1] nan [2] nan [3]